Xenon Pharmaceuticals Inc. Share Price
XENEXenon Pharmaceuticals Inc. Stock Performance
Open $40.77 | Prev. Close $40.23 | Circuit Range N/A |
Day Range $40.02 - $41.12 | Year Range $26.74 - $46.50 | Volume 84,873 |
Average Traded $40.22 |
Xenon Pharmaceuticals Inc. Share Price Chart
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
15-Jan-26 | $41.78 | $40.75 | -2.02% |
14-Jan-26 | $40.16 | $41.59 | +3.05% |
13-Jan-26 | $40.90 | $40.36 | -2.12% |
12-Jan-26 | $41.50 | $41.23 | -2.11% |
09-Jan-26 | $41.70 | $42.13 | +2.22% |
08-Jan-26 | $41.53 | $41.21 | -2.18% |
07-Jan-26 | $40.66 | $42.13 | +2.82% |